Tags

Type your tag names separated by a space and hit enter

Treatment of cutaneous leishmaniasis with intralesional sodium stibogluconate.
J Eur Acad Dermatol Venereol. 2009 Oct; 23(10):1189-92.JE

Abstract

BACKGROUND

Cutaneous leishmaniasis is endemic in Israel. Leishmania major is the most prevalent species that cause cutaneous leishmaniasis. Current treatment options are limited and there are few investigations in search of alternative ones.

OBJECTIVE

This study aims to assess our experience with intralesional sodium stibogluconate (SSG) in the treatment of cutaneous leishmaniasis.

METHODS

A retrospective evaluation for all adult cases of cutaneous leishmaniasis treated by intralesional and intravenous SSG (Pentostam, GlaxoSmithKline) between 2004 and 2006 was performed, for cases referred to a tertiary care university-affiliated medical centre in Israel. Intralesional SSG was injected at 0.5 mL per lesion (50 mg). Treatment was repeated every 2-3 weeks for a total of 12 weeks. Intravenous SSG was administered at a dose of 20 mg/kg for 10-20 days.

RESULTS

Thirty-three cases of cutaneous leishmaniasis were treated with intralesional SSG during the study period. The patients consist of 26 males and 7 females, mostly Israeli military personnel, and there were a total of 93 lesions. Within 3 months from treatment onset, 91% (30/33) had completed healing of the cutaneous lesions after an average of 3 treatments (range 1-6). Side-effects were mild and were mostly pain during injection, with two patients developing mild local site reaction after the injection.

CONCLUSIONS

Intralesional SSG treatment is safe, effective and well tolerated with minimal side-effects.

Authors+Show Affiliations

Department of Dermatology, Chaim Sheba Medical Center, Tel Hashomer, The Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

19298486

Citation

Solomon, M, et al. "Treatment of Cutaneous Leishmaniasis With Intralesional Sodium Stibogluconate." Journal of the European Academy of Dermatology and Venereology : JEADV, vol. 23, no. 10, 2009, pp. 1189-92.
Solomon M, Baum S, Barzilai A, et al. Treatment of cutaneous leishmaniasis with intralesional sodium stibogluconate. J Eur Acad Dermatol Venereol. 2009;23(10):1189-92.
Solomon, M., Baum, S., Barzilai, A., Pavlotsky, F., Trau, H., & Schwartz, E. (2009). Treatment of cutaneous leishmaniasis with intralesional sodium stibogluconate. Journal of the European Academy of Dermatology and Venereology : JEADV, 23(10), 1189-92. https://doi.org/10.1111/j.1468-3083.2009.03157.x
Solomon M, et al. Treatment of Cutaneous Leishmaniasis With Intralesional Sodium Stibogluconate. J Eur Acad Dermatol Venereol. 2009;23(10):1189-92. PubMed PMID: 19298486.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Treatment of cutaneous leishmaniasis with intralesional sodium stibogluconate. AU - Solomon,M, AU - Baum,S, AU - Barzilai,A, AU - Pavlotsky,F, AU - Trau,H, AU - Schwartz,E, Y1 - 2009/02/24/ PY - 2009/3/21/entrez PY - 2009/3/21/pubmed PY - 2009/12/16/medline SP - 1189 EP - 92 JF - Journal of the European Academy of Dermatology and Venereology : JEADV JO - J Eur Acad Dermatol Venereol VL - 23 IS - 10 N2 - BACKGROUND: Cutaneous leishmaniasis is endemic in Israel. Leishmania major is the most prevalent species that cause cutaneous leishmaniasis. Current treatment options are limited and there are few investigations in search of alternative ones. OBJECTIVE: This study aims to assess our experience with intralesional sodium stibogluconate (SSG) in the treatment of cutaneous leishmaniasis. METHODS: A retrospective evaluation for all adult cases of cutaneous leishmaniasis treated by intralesional and intravenous SSG (Pentostam, GlaxoSmithKline) between 2004 and 2006 was performed, for cases referred to a tertiary care university-affiliated medical centre in Israel. Intralesional SSG was injected at 0.5 mL per lesion (50 mg). Treatment was repeated every 2-3 weeks for a total of 12 weeks. Intravenous SSG was administered at a dose of 20 mg/kg for 10-20 days. RESULTS: Thirty-three cases of cutaneous leishmaniasis were treated with intralesional SSG during the study period. The patients consist of 26 males and 7 females, mostly Israeli military personnel, and there were a total of 93 lesions. Within 3 months from treatment onset, 91% (30/33) had completed healing of the cutaneous lesions after an average of 3 treatments (range 1-6). Side-effects were mild and were mostly pain during injection, with two patients developing mild local site reaction after the injection. CONCLUSIONS: Intralesional SSG treatment is safe, effective and well tolerated with minimal side-effects. SN - 1468-3083 UR - https://www.unboundmedicine.com/medline/citation/19298486/Treatment_of_cutaneous_leishmaniasis_with_intralesional_sodium_stibogluconate_ L2 - https://doi.org/10.1111/j.1468-3083.2009.03157.x DB - PRIME DP - Unbound Medicine ER -